Vascular Erectile Dysfunction and Subclinical Cardiovascular Disease
- PMID: 29760599
- PMCID: PMC5947968
- DOI: 10.1007/s11930-017-0137-y
Vascular Erectile Dysfunction and Subclinical Cardiovascular Disease
Abstract
Purpose of review: We review the recent literature on the hypothesized temporal relationship between subclinical cardiovascular disease (CVD), vascular erectile dysfunction (ED), and clinical CVD. In addition, we combine emerging research with expert consensus guidelines such as The Princeton Consensus III to provide a preventive cardiologist's perspective toward an ideal approach to evaluating and managing CVD and ED risk in patients.
Recent findings: Development of ED was found to occur during the progression from subclinical CVD to clinical CVD. A strong association was observed between subclinical CVD as assessed by coronary artery calcium (CAC) and carotid plaque and subsequent ED, providing evidence for the role of subclinical CVD in predicting ED. ED is also identified as a substantial independent risk factor for overt clinical CVD, and ED symptoms may precede CVD symptoms by 2-3 years.
Summary: Given the body of evidence on the relationship between subclinical CVD, ED, and clinical CVD we recommend that all men with vascular ED should undergo cardiovascular risk assessment. We further recommend using CAC scores for advanced risk assessment in patients at low-intermediate to intermediate risk (5-20% CVD risk), with risk driving subsequent lifestyle and pharmacologic treatment decisions.
Keywords: Princeton III Consensus; cardiovascular disease; coronary calcium score; erectile dysfunction; risk assessment; subclinical disease.
Conflict of interest statement
Conflict of Interest Zain Gowani, S M Iftekhar Uddin, Mohammadhassan Mirbolouk, Dawar Ayyaz, Kevin L. Billups, Martin Miner, David I. Feldman each declare no potential conflicts of interest. Michael J. Blaha reports grants from NIH, AHA, grants and personal fees from FDA, grants and personal fees from Amgen, grants from Aetna Foundation, personal fees from Novartis, personal fees from Siemens, personal fees from MedImmune, personal fees from Akcea, personal fees from Sanofi, personal fees from Regeneron outside the submitted work.
Figures

References
-
- Feldman DI, Cainzos-Achirica M, Billups KL, DeFilippis AP, Chitaley K, Greenland P, et al. Clin Cardiol. Vol. 39. Wiley Periodicals, Inc; 2016. Subclinical Vascular Disease and Subsequent Erectile Dysfunction: The Multiethnic Study of Atherosclerosis (MESA) pp. 291–8. This is the first longitudinal paper that showed subclinical CVD is a predictor of ED. This pivotal finding served as an evidence that CAC score can serve as a “disease score” and surrogate for accelerated atherosclerosis process in arteries including penile arteries and vascular ED. - PMC - PubMed
-
- Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes [Internet] 2013;6:99–109. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23300267 This systematic review and meta-analysis showed that ED can serve as an independent risk factor for CVD. It also provided evidence that the CVD risk prediction of ED is strongest among younger ages. - PubMed
-
- Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. JAMA. Vol. 294. American Medical Association; 2005. Erectile Dysfunction and Subsequent Cardiovascular Disease; p. 2996. - PubMed
-
- Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol [Internet] 2004;43:1405–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15093875. - PubMed
-
- Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, et al. Eur Heart J. Vol. 27. Oxford University Press; 2006. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial; pp. 2632–9. - PubMed
Grants and funding
LinkOut - more resources
Research Materials